American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.
D000368:Aged; D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density; D001842:Bone and Bones / Q000293:injuries; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000008:administration & dosage; D019587:Dietary Supplements; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D050723:Fractures, Bone; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control* / Q000628:therapy*; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D002136:Calcium, Dietary; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D019386:Alendronate